CClinicalTrials.gg
Status unknownNCT04265495Updated Sep 28, 2021

Dual Trigger, Urinary HCG or Recombinant HCG, Which is the Best !?

An observational study in IVF, sponsored by Al Baraka Fertility Hospital. Status unknown at 1 site in Bahrain. Open to female participants aged 22 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-28.

Sponsored by Al Baraka Fertility Hospital · Observational

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
600
Ages
22 Years to 40 Years
Sex
Female
01

Study summary

a comparative study among dual trigger, urinary HCG and recombinant HCG regarding the outcome of ICSI- antagonist cycles

Read the detailed description

a comparative study among dual trigger, urinary HCG and recombinant HCG regarding the outcome (oocyte quality, fertilization rate, implantation rate, clinical pregnancy rate as well as the incidence of OHSS) in ICSI- antagonist cycles

02

Conditions studied

  • IVF

Keywords

  • Dual trigger implantation,
  • HCG
  • OHSS
  • ANTAGONIST
03

Who can participate

Ages eligible
22 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

patients \<40 years of age who underwent IVF/ICSI cycles using a GnRH antagonist protocol, then at the time of triggering, we divided the patients to 3 groups by for triggering by a dual trigger, urinary HCG and recombinant HCG and then will check the outcome regarding the maturity and oocyte quality, implantation rate, clinical pregnancy rate as well as incidence of OHSS

Inclusion criteria

  • patients \<40 years of age who underwent IVF/ICSI cycles using a GnRH antagonist protocol

Exclusion criteria

Exclusion Criteria:

  • age: > 40 years
  • BMI > 30 ,
  • long agonist protocol
  • were chromosomal and genetic disorders, abnormal ultrasonogram of the uterine cavity
04

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
600 participants (estimated)
Patient registry
No

Groups and cohorts

  • DUAL TRIGGERING

    PATIENTS WILL RECEIVE DUAL TRIGGERING

  • URINARY HCG

    PATIENTS WILL RECEIVE URINARY HCG

  • RECOMBINANT HCG

    PATIENTS WILL RECEIVE RECOMBINANT HCG

05

What researchers measure

Primary outcomes

  1. clinical pregnancy rate,

    Time frame: 4 WEEKS

  2. implantation rate,

    Time frame: 2 WEEKS

  3. incidence of OHSS.

    Time frame: 1 WEEK

06

Study locations

1 of 1 sites recruiting
07

Registry details

Key details

Study ID
NCT04265495
Lead sponsor
Al Baraka Fertility Hospital
Responsible party
Dr. Kamal Rageh (DOCTOR, Al Baraka Fertility Hospital) — Principal investigator
First posted
Feb 11, 2020
Start date
Feb 9, 2020
Primary completion
Nov 30, 2021 (estimated)
Completion
Dec 1, 2021 (estimated)
Last update
Sep 28, 2021

Study contacts

Kamal eldin Rageh, M.D.
Contact
dr_kamal_rageh@yahoo.com
0097333153871
Ahmed Barakat, FRCOG
Contact
ahmed.barakat@yahoo.com
0097317727888

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion